Diltiazem Hydrochloride Capsules Recalled Due to Manufacturing Impurity
Glenmark Pharmaceuticals is recalling Diltiazem Hydrochloride Extended-Release Capsules (60 mg) due to presence of N-nitroso-Desmethyl-Diltiazem impurity exceeding FDA limits. Approximately 34,848 bottles nationwide are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving detection of an impurity above the FDA recommended limit, representing a risk of harm from a known genotoxic compound. No illnesses or injuries have been reported, making this a preventive manufacturing recall that fits the 'risk-of-harm products where injury has not yet been reported' criterion.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Diltiazem Hydrochloride Extended-Release Capsules, USP 60 mg (Twice-a-Day Dosage) across the United States. The recall affects approximately 34,848 bottles with the following lot numbers: 17222544 (expiration 11/30/2024), 17230784 (expiration 03/31/2025), and 17231080 (expiration 04/30/2025).
The recall was initiated due to cGMP deviations related to the presence of N-nitroso-Desmethyl-Diltiazem impurity found at levels exceeding the FDA's recommended interim limit. This impurity was detected during manufacturing quality control.
Patients taking a product from one of the affected lots should contact their healthcare provider or pharmacist for guidance. Do not abruptly stop taking this medication without consulting a healthcare professional. Affected bottles may be returned to the pharmacy or disposed of according to local regulations.
The recalled product
- Product
- DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE)
- Brand
- DILTIAZEM HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Hazard
- n-nitroso-impurity
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #s: 17222544
- Exp. Date 11/30/2024
- 17230784
- Exp Date 03/31/2025
- 17231080
- Exp. Date 04/30/2025
UPCs (3)
- 0368462562017
- 0368462851012
- 0368462850015
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DILTIAZEM HYDROCHLORIDE
- HighGlenmark Diltiazem Extended-Release Capsules recalled for manufacturing deviations
FDA (Drugs) · 2025-04-16
- HighDiltiazem Hydrochloride Capsules Recalled Due to Nitrosamine Impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem extended-release capsules recalled for manufacturing impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem Hydrochloride Extended-Release Capsules Recalled for Manufacturing Impurity
FDA (Drugs) · 2024-12-11
- HighPrescription Drug Diltiazem Hydrochloride Recalled for Manufacturing Impurity
FDA (Drugs) · 2024-12-11
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27